Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$111.25
-1.9%
$116.18
$74.37
$125.14
$275.02B0.1810.94 million shs4.89 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.67
-2.5%
$39.61
$35.12
$81.44
$199.48B0.7721.71 million shs12.97 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.30
-1.8%
$27.01
$22.45
$28.75
$144.27B0.3542.33 million shs27.22 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.32%+0.87%-5.62%-6.74%+54.10%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
Pfizer Inc. stock logo
PFE
Pfizer
-0.83%-2.78%-5.12%-6.65%+16.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$111.25
-1.9%
$116.18
$74.37
$125.14
$275.02B0.1810.94 million shs4.89 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.67
-2.5%
$39.61
$35.12
$81.44
$199.48B0.7721.71 million shs12.97 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.30
-1.8%
$27.01
$22.45
$28.75
$144.27B0.3542.33 million shs27.22 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.32%+0.87%-5.62%-6.74%+54.10%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
Pfizer Inc. stock logo
PFE
Pfizer
-0.83%-2.78%-5.12%-6.65%+16.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$128.1815.16% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5647.68% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.8414.07% Upside

Current Analyst Ratings Breakdown

Latest NVO, PFE, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingNeutral
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/6/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageNeutral$125.00
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Reiterated RatingHold (C+)
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Lower Price TargetOverweight$150.00 ➝ $145.00
4/29/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$26.00 ➝ $27.00
4/22/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
DowngradeHold (C-)Sell (D+)
4/20/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$25.00
4/16/2026
Pfizer Inc. stock logo
PFE
Pfizer
Initiated CoverageOutperform$33.00
4/13/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$130.00 ➝ $145.00
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.23$11.21 per share9.93$18.60 per share5.98
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.24$4.42 per share10.04$7.12 per share6.24
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.30$4.29 per share5.90$15.86 per share1.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5531.3511.392.5513.59%27.55%10.73%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2610.4112.914.1937.23%63.31%22.19%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.308.84N/A11.83%19.44%8.41%N/A

Latest NVO, PFE, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.403.05%+5.75%95.77%14 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.94%+21.74%41.08%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.80%-13.20%131.30%16 Years

Latest NVO, PFE, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Pfizer Inc. $PFE Shares Sold by Pinnacle Associates Ltd.
Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
2 Ways to Play the Big Pharma Patent Cliff (PFE)
...
Pfizer's Turnaround Is Taking Shape

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$111.25 -2.16 (-1.91%)
As of 03:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$44.67 -1.13 (-2.47%)
As of 03:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$25.30 -0.45 (-1.76%)
As of 03:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.